In a new Nature Genetics paper our researchers identified a synthetic lethal interaction in 50% of cancers. Tumors lacking CDS1 depend entirely on CDS2. Blocking CDS2 kills cancer cells while sparing healthy tissue ➡️ www.nki.nl/news-events/...

The SMR 2025 Annual Congress (Amsterdam Oct 25-28) covers basic, preclinical & translational melanoma research of international top investigators. It is a very enjoyable conference with top faculty and now improved with ample opportunity for young investigators to network. Join us! smrcongress.org

Major congratulations to my PhD student Tim Arnoldus @nkinl.bsky.social @oncodeinstitute.bsky.social ‬on publishing his exciting discovery today in Nature Genetics! 🎉 By computational mining Tim found a synthetic lethal target that may impact future treatment of half of all cancers.👏 t.co/cQdeYQinsX

Congrats to Sofía Ibáñez Molero @NKI_nl and @oncodeinstitute for excellently defending her PhD thesis, on functional interactions between cancer and the immune system, with several interesting papers already published and under review. Great work Sofía and best of luck with your postdoc!

📢 Applications for the NKI PhD program now open till Feb 28. Several exciting positions available, including one in my lab on discovering new biology and therapeutic opportunities of a population of enriched tumor-reactive T cells we recently identified. www.nki.nl/careers-stud...

More knowledge about immunotherapy, advanced diagnostics, and reducing overtreatment. Thanks to financial support from KWF Dutch Cancer Society, 13 research teams from the Netherlands Cancer Institute are launching new projects ➡️ www.nki.nl/news-events/...

📢 Applications for the NKI PhD program open from Jan 1 - Feb 28. Join our international research community in Amsterdam, working in cancer biology, AI research & life sciences with leading scientists and top facilities #PhD #CancerResearch More info: bit.ly/3O4bOjq

My first post here: Congrats to David Vredevoogd from my lab @NKI_nl @oncodeinstitute + collaborators for reporting on TMED, a new regulator of both immune checkpoints PD-1 and CTLA-4, which is amenable to therapeutic intervention. Read the paper here jitc.bmj.com/content/12/1...